Skip to main content

Table 1 Patient demographics a

From: Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria

Age, yr Tumor type (IDC, 1) (IDC/ILC, 1) (ILC, 0 ) Nottingham score (out of 9) Mitotic count/10 hpf Triple-negative (+, 1) (−, 0) HER2 (+, 1) (−, 0) ER (+, 0) (−, 1) Miller-Payne grade
32 1 9 20 0 0 0 2
51 1 8 8 0 0 0 2
42 1 8 8 1 0 1 5
64 1 9 34 1 0 1 5
48 1 4 0 1 0 1 3
34 1 6 2 0 0 0 1
39 0 7 1 0 0 0 2
48 1 5 6 0 0 0 1
39 1 9 14 1 0 1 1
42 0 3 0 0 0 0 1
35 1 9 39 0 0 0 4
40 1 4 2 0 0 0 2
47 1 9 15 0 0 0 5
53 0 6 0 or 1 0 0 0 2
32 1 9 16 0 1 1 4
64 1 6 4 0 1 1 4
40 1 9 30 0 1 0 3
38 1 7 9 0 1 0 4
64 1 8 44 0 0 0 2
48 0 6 1 0 0 0 2
69 1 7 16 0 0 0 3
82 1 6 0 0 0 0 1
47b 1 8 10 0 0 0 5
38 1 9 20 1 0 1 5
49 1 6 8 0 0 0 3
63b 1 8 10 0 0 0 3
37 1 7 8 0 0 0 4
55 1 7 10 0 1 0 5
44 1 6 5 0 0 0 3
53 1 9 58 1 0 1 5
54 1 9 26 0 0 1 5
42 0 6 5 0 0 0 2
77 1 9 16 0 1 0 5
35 1 6 4 0 0 0 3
  1. aER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; hpf, High-power fields; IDC, Invasive ductal carcinoma; IDC/ILC, Invasive mammary carcinoma with mixed ductal and lobular features; ILC, Invasive lobular carcinoma. bTwo distinct tumors in the same breast with the same characteristics.